Cholesteryl hyaluronic acid-coated, reduced graphene oxide nanosheets for anti-cancer drug delivery
- Authors
- Miao, Wenjun; Shim, Gayong; Kang, Choong Mo; Lee, Soondong; Choe, Yearn Seong; Choi, Han-Gon; Oh, Yu-Kyoung
- Issue Date
- Dec-2013
- Publisher
- ELSEVIER SCI LTD
- Keywords
- Hyaluronic acid; Graphene-based nanosheets; Doxorubicin; Anti-tumor effect
- Citation
- BIOMATERIALS, v.34, no.37, pp.9638 - 9647
- Indexed
- SCIE
SCOPUS
- Journal Title
- BIOMATERIALS
- Volume
- 34
- Number
- 37
- Start Page
- 9638
- End Page
- 9647
- URI
- https://scholarworks.bwise.kr/erica/handle/2021.sw.erica/26278
- DOI
- 10.1016/j.biomaterials.2013.08.058
- ISSN
- 0142-9612
- Abstract
- Here, we report hyaluronyl reduced graphene oxide (rGO) nanosheets as a tumor-targeting delivery system for anticancer agents. Hyaluronyl-modified rGO nanosheets were prepared by synthesizing cholesteryl hyaluronic acid (CHA) and using it to coat rGO nanosheets, yielding CHA-rGO. Compared with rGO, CHA-rGO nanosheets showed increased colloidal stability under physiological conditions and improved in vivo safety, with a survival rate of 100% after intravenous administration of 40 mg/kg in mice. The doxorubicin (Dox) loading capacity of CHA-rGO was 4-fold greater than that of rGO. Uptake of Dox by CD44-overexpressing KB cells was higher for CHA-rGO than for rGO, and was decreased in the presence of hyaluronic acid through competition for CD44 receptor binding. After intravenous administration in tumor-bearing mice, CHA-rGO/Dox showed higher tumor accumulation than rGO/Dox. The in vivo antitumor efficacy of Dox delivered by CHA-rGO was significantly increased compared with free Dox or rGO/Dox. In CHA-rGO/Dox-treated mice, tumor weights were reduced to 14.1% +/- 0.1% of those in untreated mice. Our findings indicate that CHA-rGO nanosheets possess greater stability, safety, drug-loading capacity, and CD44-mediated delivery of Dox than rGO nanosheets. These beneficial properties of CHA-rGO improved the distribution of Dox to tumors and facilitated the cellular uptake of Dox by CD44-overexpressing tumor cells, resulting in enhanced anticancer effects. (C) 2013 Elsevier Ltd. All rights reserved.
- Files in This Item
-
Go to Link
- Appears in
Collections - COLLEGE OF PHARMACY > DEPARTMENT OF PHARMACY > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/erica/handle/2021.sw.erica/26278)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.